Phospholipase A2 enzymes and the risk of atherosclerosis (Q26830664)

E. Hurt-Camejo

series ordinal

2

1 reference

language of work or name

1 reference

December 2012

1 reference

published in

European Heart Journal

1 reference

volume

33

1 reference

page(s)

2899-909

1 reference

issue

23

1 reference

Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies

cites work

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Low-molecular-weight, calcium-dependent phospholipase A2 genes are linked and map to homologous chromosome regions in mouse and human

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Level of circulating phospholipase A2 in prediction of the prognosis of patients with suspected myocardial infarction

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Inhibition of type 2A secretory phospholipase A2 reduces death of cardiomyocytes in acute myocardial infarction.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Phospholipase A2 biochemistry

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2).

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: the epidemiological evidence

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Future role for selective phospholipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Anti-inflammatory effects of varespladib methyl in diabetic patients with acute coronary syndrome

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Lipoprotein-associated phospholipase A2 gene V279F polymorphisms and coronary heart disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Role of secretory phospholipases in atherogenesis

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Lipidomics: a tool for studies of atherosclerosis

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Secretory phospholipase A2: a multifaceted family of proatherogenic enzymes

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Alterations in the physiochemical characteristics of low and high density lipoproteins after lipolysis with phospholipase A2. A spin-label study

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Lipoprotein-associated phospholipase A2 activity improves risk discrimination of incident coronary heart disease among women

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Lysophospholipids: effectors mediating the contribution of dyslipidemia to calcification associated with atherosclerosis

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

CRP, interleukin-6, secretory phospholipase A2 group IIA, and intercellular adhesion molecule-1 during the early phase of acute coronary syndromes and long-term follow-up

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, dou

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Recent progress in phospholipase A₂ research: from cells to animals to humans

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Secretory type II phospholipase A(2) binds to ischemic myocardium during myocardial infarction in humans

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Lp-PLA(2) and risk of atherosclerotic vascular disease

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Receptors for a growing family of secreted phospholipases A2.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Potent, orally active inhibitors of lipoprotein-associated phospholipase A(2): 1-(biphenylmethylamidoalkyl)-pyrimidones

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Structure-based design of a new class of anti-inflammatory drugs: secretory phospholipase A(2) inhibitors, SPI.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Platelet-activating factor acetylhydrolases: broad substrate specificity and lipoprotein binding does not modulate the catalytic properties of the plasma enzyme

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Role of group IIa and group V secretory phospholipases A(2) in the metabolism of lipoproteins. Substrate specificities of the enzymes and the regulation of their activities by sphingomyelin

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Recombinant production and properties of binding of the full set of mouse secreted phospholipases A2 to the mouse M-type receptor.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

High plasma phospholipase A2 activity, inflammation markers, and LDL alterations in obesity with or without type 2 diabetes

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

How cholesterol homeostasis is regulated by plasma membrane cholesterol in excess of phospholipids

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Secretory phospholipase A2-IID is an effector molecule of CD4+CD25+ regulatory T cells

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

The human 180-kDa receptor for secretory phospholipases A2. Molecular cloning, identification of a secreted soluble form, expression, and chromosomal localization

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Phospholipase A(2) modification of low density lipoproteins forms small high density particles with increased affinity for proteoglycans and glycosaminoglycans

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Functional association of type IIA secretory phospholipase A(2) with the glycosylphosphatidylinositol-anchored heparan sulfate proteoglycan in the cyclooxygenase-2-mediated delayed prostanoid-biosynthetic pathway

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Group X secreted phospholipase A2 proenzyme is matured by a furin-like proprotein convertase and releases arachidonic acid inside of human HEK293 cells

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Interfacial kinetic and binding properties of the complete set of human and mouse groups I, II, V, X, and XII secreted phospholipases A2.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Potentiation of tumor necrosis factor alpha-induced secreted phospholipase A2 (sPLA2)-IIA expression in mesangial cells by an autocrine loop involving sPLA2 and peroxisome proliferator-activated receptor alpha activation.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Intracellular actions of group IIA secreted phospholipase A2 and group IVA cytosolic phospholipase A2 contribute to arachidonic acid release and prostaglandin production in rat gastric mucosal cells and transfected human embryonic kidney cells

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Macrophage secretory phospholipase A2 group X enhances anti-inflammatory responses, promotes lipid accumulation, and contributes to aberrant lung pathology

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Group V secretory phospholipase A2 plays a pathogenic role in myocardial ischaemia-reperfusion injury.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Inflammatory biomarkers, physical activity, waist circumference, and risk of future coronary heart disease in healthy men and women

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Tagging-SNP haplotype analysis of the secretory PLA2IIa gene PLA2G2A shows strong association with serum levels of sPLA2IIa: results from the UDACS study

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Atherogenic properties of LDL particles modified by human group X secreted phospholipase A2 on human endothelial cell function.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Phospholipase A2 and small, dense low-density lipoprotein

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/- mice

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Fatty acid-induced atherogenic changes in extracellular matrix proteoglycans

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Expression of type V secretory phospholipase A in myocardial remodelling after infarction

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Lipoprotein-associated phospholipase A₂ activity and mass in relation to vascular disease and nonvascular mortality

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Physiochemically modified apolipoprotein B-containing lipoproteins and the risk of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

The C-type lectin-like domain superfamily

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Biochemistry and physiology of mammalian secreted phospholipases A2.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Macrophage-expressed group IIA secretory phospholipase A2 increases atherosclerotic lesion formation in LDL receptor-deficient mice

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Molecular mechanism for changes in proteoglycan binding on compositional changes of the core and the surface of low-density lipoprotein-containing human apolipoprotein B100.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Secretory phospholipase A2 group V: lesion distribution, activation by arterial proteoglycans, and induction in aorta by a Western diet

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Group v secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Role of group II secretory phospholipase A2 in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Lipolysis of LDL by Human Secretory Phospholipase A 2 Induces Particle Fusion and Enhances the Retention of LDL to Human Aortic Proteoglycans

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

George Lyman Duff memorial lecture. Progression and regression of atherosclerotic lesions. Insights from lipid physical biochemistry.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE).

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Association of a G994-->T missense mutation in the plasma platelet-activating factor acetylhydrolase gene with genetic susceptibility to nonfamilial dilated cardiomyopathy in Japanese

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Molecular basis for the association of group IIA phospholipase A(2) and decorin in human atherosclerotic lesions

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

The capacity of group V sPLA2 to increase atherogenicity of ApoE-/- and LDLR-/- mouse LDL in vitro predicts its atherogenic role in vivo

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Group X secretory phospholipase A2 negatively regulates ABCA1 and ABCG1 expression and cholesterol efflux in macrophages

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Circulating platelet-activating factor is primarily cleared by transport, not intravascular hydrolysis by lipoprotein-associated phospholipase A2/ PAF acetylhydrolase

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Reduction in myocardial ischemia/reperfusion injury in group X secretory phospholipase A2-deficient mice

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

The sPLA2 Inhibition to Decrease Enzyme Release after Percutaneous Coronary Intervention (SPIDER-PCI) trial.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Phospholipase A(2) in vascular disease

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

A-002 (Varespladib), a phospholipase A2 inhibitor, reduces atherosclerosis in guinea pigs

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Macrophage-specific expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stress

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

The synergistic inhibition of atherogenesis in apoE-/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002).

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Carriage of the V279F null allele within the gene encoding Lp-PLA₂ is protective from coronary artery disease in South Korean males

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Type II secretory phospholipase A2 and prognosis in patients with stable coronary heart disease: mendelian randomization study

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

1 reference

7 January 2021

The application of rational design on phospholipase A(2) inhibitors.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

After FRANCIS: next steps in the clinical evaluation of varespladib methyl

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Lipoprotein-associated phospholipase A2 activity and incident coronary heart disease among men and women with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021

Integrated lipidomics in the secreted phospholipase A(2) biology

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHS148

7 January 2021